| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0751292e8eb6f03de65b670b517e79e0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2de3beee83d9c19278da409b72c777a8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_75dc484f88d3915c3483c37631e629b3 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-205
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5575 |
| filingDate |
2007-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41558469223ec63a696235e273e18c2f |
| publicationDate |
2008-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2008023784-A1 |
| titleOfInvention |
Agent for amelioration of ophthalmic circulatory disorder |
| abstract |
Disclosed is an agent for ameliorating an ophthalmic circulatory disorder for orally administering limaprost to a patient with the ophthalmic circulatory disorder in an amount of 5 to 50 μg per day for a period of 2 to 72 weeks. The agent can be administered orally to ameliorate the ophthalmic circulatory disorder, and treat a symptom induced by the ophthalmic circulatory disorder and/or prevent the progress of the symptom. Further, the agent can shorten the period required for disappearance of the hemorrhage of the optic fundus associated with the ophthalmic circulatory disorder and also shorten the period required for the recovery of decreased visual acuity and/or the amelioration of a visual field disorder. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103561748-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8889735-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012229209-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012137987-A1 |
| priorityDate |
2006-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |